A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults

Inclusion Criteria:

- Subjects who the investigator believes can and will comply with the requirements of
the protocol

- A male or female 18 years of age or older, in stable health, as established by medical
history and physical examination before entering into the study.

- Written informed consent obtained from the subject.

- Access to a consistent means of telephone contact, which may be either in the home or
at the workplace, land line, or mobile, but NOT a pay phone or other multiple-user
device.

- Female subjects of non-childbearing potential may be enrolled in the study.

- Female subjects of childbearing potential may be enrolled in the study, if the
subject:

- - has practiced adequate contraception for 30 days prior to vaccination, and

- - has a negative pregnancy test on the day of vaccination, and

- - has agreed to continue adequate contraception during the entire treatment period and
for 2 months after completion of the vaccination series.

Exclusion Criteria:

- Use of an investigational / non-registered product other than the study vaccines
within 30 days before study vaccination or planned use during study period.

- Planned administration or administration of a licensed vaccine within 30 days before
study vaccination.

- Prior receipt of 2010/2011 influenza vaccine.

- Receipt of any investigational or approved influenza vaccine within six months of the
first study visit.

- Any known or suspected allergy to any constituent of influenza vaccines ; a history of
anaphylactic-type reaction to constituent of vaccine; or a history of severe adverse
reaction to a previous influenza vaccine.

- History of any reaction or hypersensitivity likely to be exacerbated by any component
of the vaccines.

- History of Guillain-Barre syndrome within 6 weeks of receipt of prior inactivated
influenza virus vaccine.

- Presence or evidence of substance abuse or of neurological or psychiatric diagnoses
which, even if clinically stable, are deemed by the investigator to render the
potential subject unable / unlikely to provide accurate safety reports.

- Acute, clinically significant pulmonary, cardiovascular, hepatic or renal functional
abnormality, based on history and physical examination.

- Presence of significant uncontrolled chronic medical or neuropsychiatric illness,
based on history and physical examination

- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
medical history and physical examination.

- Any significant disorder of coagulation or treatment with Coumadin derivatives or
heparin

- Chronic administration of immunosuppressants or other immune-modifying drugs within 3
months prior to the first vaccine/product dose.

- Administration of immunoglobulins and/or any blood products within the 3 months
preceding the first dose of study vaccine or planned administration during the study
period.

- Pregnant or lactating female.

- Fever at the time of enrolment.

- Acute disease at the time of enrolment

- Any other condition which, in the opinion of the Investigator, prevents the subject
from participating in the study.